You are here:
cannabinoid (Sativex)
Advice
in the absence of a submission from the holder of the marketing authorisation
cannabinoid oromucosal spray (Sativex®) is not recommended for use within NHS Scotland.
Indication under review: as an add-on treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Drug Details
| Drug Name: | cannabinoid (Sativex) |
|---|---|
| SMC Drug ID: | 703/11 |
| Manufacturer: | Bayer plc/Bayer Schering Pharma |
| Indication: | as an add-on treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy. |
| BNF Category: | |
| Sub Category: | 10.2 Drugs used in neuromuscular disorders |
| Submission Type: | Non submission |
| Status: | Not Recommended |
| Date Advice Published: | 11 April 2011 |